Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 387

1.

Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients.

Horio T, Iwashima Y, Kamide K, Tokudome T, Yoshihara F, Nakamura S, Kawano Y.

J Hypertens. 2010 Aug;28(8):1738-44. doi: 10.1097/HJH.0b013e32833a7dfe.

PMID:
20485194
2.

In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.

Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Nieminen MS, Olsen MH, Okin PM, Palmieri V, Rokkedal JE, Devereux RB.

Blood Press. 2010 Jun;19(3):169-75. doi: 10.3109/08037051.2010.481811.

PMID:
20438307
3.

Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.

Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB.

Circ Arrhythm Electrophysiol. 2008 Dec;1(5):337-43. doi: 10.1161/CIRCEP.108.795351. Epub 2008 Dec 2.

4.

Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.

Ariansen I, Reims HM, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM, Kjeldsen SE, Dahlöf B, Wachtell K.

Blood Press. 2012 Feb;21(1):6-11. doi: 10.3109/08037051.2011.622978. Epub 2011 Nov 10.

PMID:
22070095
5.

Echocardiographic assessment of the cardio-renal connection: is left ventricular hypertrophy or diastolic function more closely correlated with estimated glomerular filtration rate in patients with cardiovascular risk factors?

Masugata H, Senda S, Goda F, Yamagami A, Okuyama H, Kohno T, Hosomi N, Yukiiri K, Noma T, Imai M, Kiyomoto H, Nishiyama A, Kohno M.

Clin Exp Hypertens. 2010 Jan;32(2):113-20. doi: 10.3109/10641960902993145.

PMID:
20374184
6.
7.

Prognostic significance of home blood pressure control on renal and cardiovascular outcomes in elderly patients with chronic kidney disease.

Okada T, Nakao T, Matsumoto H, Nagaoka Y, Tomaru R, Iwasawa H, Wada T.

Hypertens Res. 2009 Dec;32(12):1123-9. doi: 10.1038/hr.2009.165. Epub 2009 Oct 9.

PMID:
19816503
8.

The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.

Arase Y, Suzuki F, Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kato K, Tanabe M, Ogawa K, Hara S, Kobayashi T.

Intern Med. 2011;50(10):1081-7. Epub 2011 May 1.

9.

Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study.

Tsioufis C, Vezali E, Tsiachris D, Dimitriadis K, Taxiarchou E, Chatzis D, Thomopoulos C, Syrseloudis D, Stefanadi E, Mihas C, Katsi V, Papademetriou V, Stefanadis C.

J Hypertens. 2009 Apr;27(4):744-52. doi: 10.1097/HJH.0b013e32832401ff.

PMID:
19516174
10.

Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.

Ravera M, Noberasco G, Re M, Filippi A, Gallina AM, Weiss U, Cannavò R, Ravera G, Cricelli C, Deferrari G.

Nephrol Dial Transplant. 2009 May;24(5):1528-33. doi: 10.1093/ndt/gfn692. Epub 2008 Dec 10.

11.

Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A; ALLHAT Collaborative Research Group.

J Am Coll Cardiol. 2009 Nov 24;54(22):2023-31. doi: 10.1016/j.jacc.2009.08.020.

12.

Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.

Omae K, Ogawa T, Nitta K.

Heart Vessels. 2010 May;25(3):203-8. doi: 10.1007/s00380-009-1188-4. Epub 2010 May 29.

PMID:
20512447
13.

Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality.

Tsagalis G, Akrivos T, Alevizaki M, Manios E, Stamatellopoulos K, Laggouranis A, Vemmos KN.

Nephrol Dial Transplant. 2009 Jan;24(1):194-200. doi: 10.1093/ndt/gfn471. Epub 2008 Aug 26.

14.

Strict blood-pressure control and progression of renal failure in children.

ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F.

N Engl J Med. 2009 Oct 22;361(17):1639-50. doi: 10.1056/NEJMoa0902066.

15.

Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease.

Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS.

Circulation. 2013 Feb 5;127(5):569-74. doi: 10.1161/CIRCULATIONAHA.112.123992. Epub 2012 Dec 28.

16.

[SFAAT: the study of nonrheumatic chronic atrial fibrillation in the Trieste area. Results of an enrollment study].

Scardi S, Mazzone C, Goldstein D, Pandullo C, Poletti A, Humar F, Pivotti F, De Santis C.

G Ital Cardiol. 1995 Feb;25(2):173-82. Italian.

PMID:
7642022
17.

[Risk factors and pathogenetic mechanisms of left ventricular hypertrophy in progressive chronic kidney disease and after transplantation of the kidney].

Tomilina NA, Storozhakov GI, Gendlin GE, Badaeva SV, Zhidkova DA, Kim IG, Borisovskaia SV, Loss KE, Fedorova ND.

Ter Arkh. 2007;79(6):34-40. Russian.

PMID:
17684964
18.

[Atrial fibrillation: prevalence, risk factors and mortality in a large French population with 15 years of follow-up].

Guize L, Thomas F, Bean K, Benetos A, Pannier B.

Bull Acad Natl Med. 2007 Apr-May;191(4-5):791-803; discussion 803-5. French.

PMID:
18225434
19.

Risk factors for progression in patients with early-stage chronic kidney disease in the Japanese population.

Yoshida T, Takei T, Shirota S, Tsukada M, Sugiura H, Itabashi M, Ogawa T, Uchida K, Tsuchiya K, Nitta K.

Intern Med. 2008;47(21):1859-64. Epub 2008 Nov 4.

20.

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB.

J Am Coll Cardiol. 2005 Mar 1;45(5):712-9.

Items per page

Supplemental Content

Write to the Help Desk